Hyponatremia screening: Difference between revisions
Jump to navigation
Jump to search
| Line 19: | Line 19: | ||
* 1–2 weeks after initiation of [[Thiazides|thiazide]], [[Serotonin-norepinephrine reuptake inhibitor|SNRI]], and [[Selective serotonin reuptake inhibitor|SSRI]] therapy, especially in patients at high risk for hyponatremia. | * 1–2 weeks after initiation of [[Thiazides|thiazide]], [[Serotonin-norepinephrine reuptake inhibitor|SNRI]], and [[Selective serotonin reuptake inhibitor|SSRI]] therapy, especially in patients at high risk for hyponatremia. | ||
* All hospitalized patients on admission | * All hospitalized patients on admission | ||
* | |||
* | |||
==References== | ==References== | ||
Revision as of 16:05, 24 May 2018
|
Hyponatremia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hyponatremia screening On the Web |
|
American Roentgen Ray Society Images of Hyponatremia screening |
|
Risk calculators and risk factors for Hyponatremia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
Plasma sodium should be check in
- 1–2 weeks after initiation of thiazide, SNRI, and SSRI therapy, especially in patients at high risk for hyponatremia.
- All hospitalized patients on admission